Health 360 runs an accredited system to test for mutations in genes that indicate increased risk for cancers including, but not limited to, breast, ovarian, colon, and endometrial. With Hereditary Cancer Screening, we can predict whether a patient carries BRCA1 and BRCA2 gene mutations, which are strong risk indicators for breast and ovarian cancers. According to the CDC, BRCA1 and BRCA2 mutations account for 20%-25% of hereditary breast cancers. The Cancer Panel will also test for changes in 30 additional genes, including APC, ATM, BARD1, BMPR1A, BRIP1, CDH1, CDKN2A, CHEK2, EPCAM, FH, FLCN, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, PTEN, RAD50, RAD51C, RAD51D, RINT1, SDHB, SMAD4, STK11, TP53, VHL, and XRCC2. This will inform patients about risks associated with breast, ovarian, colon, and uterine cancers. This inclusive panel provides a deep view into the genetic risks of cancer development. If you decide testing is the right thing to do, risk screening can be done for women and men as early as age 19!
We offer genetic testing to cover a wide range of inherited cancer risk factors and personalized drug sensitivities. Our accredited and FDA-approved testing provides the highest level of results accuracy. The proprietary and personalized intra-office software we use establishes medical justification for at risk patients. We consistently provide actionable test results in our easy-to-read genetic test reports. Our software unifies clinical offices and our specialized laboratories with an efficient ordering process to provide a streamline source of communication between physicians, patients, and our laboratory staff.